Chromadex is a science-based ingredient company best known for its flagship ingredient Niagen, a form of vitamin B3.
Evaluating Chromadex net worth involves looking at revenue streams, partnerships, ingredient demand, and the broader nutraceutical market dynamics.
| Metric | 2023 | 2024 | 2025 (estimated) |
|---|---|---|---|
| Annual Revenue | $55-60 million | $48-52 million | $50-58 million |
| Reported Net Worth | Not publicly disclosed | Private valuation estimates | Market-based range |
| Active Partnerships | 40+ global partners | 35+ ongoing programs | Expansion in Asia |
| Core Ingredient | Niagen (Nicotinamide Riboside) | ||
Science and Clinical Research Behind Niagen
Mechanism of Action
Niagen increases NAD+ levels, a coenzyme involved in cellular energy metabolism and DNA repair.
Published Studies
Peer-reviewed research links Niagen to improved cognitive function, metabolic health, and longevity pathways.
Market Position in Nutraceuticals
Brand Recognition
Chromadex benefits from long-term contracts and trusted relationships with major retailers and supplement brands.
Competitive Landscape
The company competes with other NAD+ precursors and premium ingredient suppliers focused on aging and energy.
Revenue Streams and Business Model
Direct Sales
Chromadex sells Niagen in bulk to manufacturers, co-packers, and retail chains.
Licensing and Royalties
Patent-protected formulations generate ongoing income and strengthen market exclusivity.
Financial Health and Outlook
Profitability Trends
Consistent gross margins reflect ingredient quality and strong demand across demographics.
Growth Drivers
Expanding into Asia, personalized nutrition, and anti-aging categories support long-term valuation upside.
FAQ
Is Chromadex publicly traded or privately held?
Chromadex is a privately held company, so detailed financial statements and official net worth figures are not disclosed publicly.
How is Chromadex net worth estimated by analysts?
Analysts rely on revenue multiples, partnership pipelines, and ingredient demand to model a private valuation range.
What risks could lower Chromadex valuation?
Regulatory changes, competition, and supply chain disruptions in raw material sourcing may pressure future growth.
Does Chromadex have patents protecting Niagen?
Yes, Chromadex holds patents related to the manufacturing and use of Niagen, supporting premium pricing.
Key Takeaways on Chromadex Net Worth
- Focus on Niagen as a scientifically backed NAD+ precursor drives ingredient demand.
- Private ownership limits transparency but allows flexible long-term strategy.
- Revenue stability comes from global partnerships and contract manufacturing.
- Growth in aging and wellness markets supports future valuation upside.
